Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 47, 2023 - Issue 4
88
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

The Spectrum of HBB Mutations among 2315 Beta Thalassemia Patients of a Reference Clinic in Tehran-Iran

, , , , , & show all
Pages 147-151 | Received 24 Aug 2022, Accepted 21 Jul 2023, Published online: 07 Aug 2023
 

Abstract

Beta Thalassemia is the most prevalent and well-studied single gene disorder in Iran. Here, we investigated the spectrum of HBB gene mutations, identified among 2315 patients, referred to a reference thalassemia clinic in Tehran, on the basis of suspicion to thalassemia major or intermedia. The patients were homozygous or compound heterozygous for HBB mutations, and were referred from various Iranian provinces, during 15 years (2001- 2016). The HBB mutations were classified based on their frequency, and the result was compared to a meta-analysis of 14,293 beta thalassemia cases in the Iranian population, within the same time period. The mutation spectrum in this study contained 43 HBB mutations, compared to the 90, presented by the meta-analysis. Similar to the meta-analysis, IVSII-1 (G > A) and IVSI-5 (G > C) were the most common mutations in this study. These two comprised 62.40% of the total HBB mutant alleles in the studied population, comparable to 51.92% of that in the meta-analysis. IVSII-1 (G > A) and IVSI-5 (G > C), followed by 17 other mutations that had frequencies ranging from 0.15% to 5.44%, were among the 20 common HBB mutations in Iran and neighboring countries, according to the meta-analysis. This study provided further evidence to support the spectrum of the most common HBB mutations in the Iranian population.

Acknowledgements

The authors thank National Institute for Medical Research Development (NIMAD), Tehran, Iran grant# 978593 for their support. The authors also acknowledge the support of the Deputy of research, University of Social Welfare and Rehabilitation Sciences T-2517, ir.uswr.rec.1400.057.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

National Institute for Medical Research Development (NIMAD), Tehran, Iran grant# 978593.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.